The following are the active pre-clinical and clinical stage development programs at Enterin, as of March 1, 2021.

Enterin has an innovative discovery engine with several exciting molecules at different stages of development. Our molecules are synthetic derivatives of either shark or mammalian aminosterols. Our lead molecule, ENT-01, is being advanced through clinical development for the treatment of Parkinson’s Disease and other potential neurodegenerative diseases. Currently, we are investigating the benefit of ENT-01 in the treatment of various non-motor symptoms of Parkinson’s Disease, including psychosis (hallucinations), dementia, and constipation.

Learn more about our lead programs.

ENT-01 (Oral)
PD + Constipation
Phase 2b
ENT-01 (Oral)
PD + Psychosis
Phase 2a (H1 2021 start)
ENT-01 (Oral)
PD + Dementia / NMS
Phase 2a (H2 2021 start)
ENT-01 (Oral)
Autism
Phase 2a (2022 start)
ENT-03 (Subcutaneous)
Obesity/Diabetes
Phase 1 (H1 2022 start)
ENT-03 (Subcutaneous)
Alzheimer’s Disease
Phase 1 (H1 2022 start)
ENT-06 (Oral)
Undisclosed
Pre-Clinical